close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

2.670 -0.090 (-3.26%)
Streaming Delayed Price Updated: 2:52 PM EDT, Aug 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptevo Therapeutics Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Aptevo Stock Jumps As Acute Myeloid Leukemia Combo Therapy Achieves 100% Clinical Benefit Rate ↗
 
Via Benzinga
5 Value Stocks In The Healthcare Sector ↗
 
Via Benzinga
News headline image
Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
Via ACCESSWIRE
News headline image
Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
Via ACCESSWIRE
News headline image
Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket ↗
Gainers Netcapital Inc. (NASDAQ: NCPL) shares rose 91.3% to $2.65 in pre-market trading following Q2 results. Netcapital posted Q2 earnings of $0.04 per share on sales of $1.78 million. 
Via Benzinga
News headline image
Dow Surges Over 250 Points; Weber Shares Spike Higher ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 250 points on Monday 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  Thursday saw 177 companies set new 52-week lows. 
Via Benzinga
News headline image
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND
Via ACCESSWIRE
News headline image
Aptevo Therapeutics: Q2 Earnings Insights ↗
  Aptevo Therapeutics (NASDAQ:APVO) reported its Q2 earnings results on Thursday, August 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Recap: Aptevo Therapeutics Q1 Earnings ↗
Aptevo Therapeutics (NASDAQ:APVO) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session ↗
Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share. 
Via Benzinga
News headline image
Crude Oil Rises Sharply; Adicet Bio Shares Plunge ↗
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 250 points on Monday 
Via Benzinga
News headline image
US Stocks Higher; Dow Rises Over 100 Points ↗
U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Monday 
Via Benzinga
News headline image
Why Aptevo Therapeutics Shares Are Trading Higher By More Than 100%; Here Are 28 Stocks Moving Premarket ↗
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)
Via ACCESSWIRE
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
We're starting off the week with a look at the biggest pre-market stock movers traders need to know about for Monday morning! 
Via InvestorPlace
News headline image
Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics
Via ACCESSWIRE
News headline image
Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to Date 
From Aptevo Therapeutics
Via AccessWire
News headline image
91 Biggest Movers From Friday ↗
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto. 
Via Benzinga
News headline image
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology... 
From Aptevo Therapeutics
Via AccessWire
News headline image
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant Disease SEATTLE, WA / ACCESSWIRE / April 12, 2022 / Aptevo... 
From Aptevo Therapeutics
Via AccessWire
News headline image
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia
Patients in Both Monotherapy and Combination Arms in Multi-Cohort Trial Have Achieved Transplant Eligible Status SEATTLE, WA / ACCESSWIRE / March 29, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a... 
From Aptevo Therapeutics
Via AccessWire
News headline image
Aptevo Therapeutics Earnings Perspective: Return On Capital Employed ↗
According to Benzinga Pro data, during Q4, Aptevo Therapeutics (NASDAQ:APVO) posted sales of $3.67 million. Earnings were up 10.36%, but Aptevo Therapeutics still reported an... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.